Realta Investment Advisors Has $667,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Realta Investment Advisors lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 69.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,056 shares of the medical research company’s stock after purchasing an additional 846 shares during the quarter. Realta Investment Advisors’ holdings in Amgen were worth $667,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC acquired a new stake in Amgen during the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC purchased a new stake in shares of Amgen in the second quarter valued at $33,000. Matrix Trust Co acquired a new stake in shares of Amgen in the third quarter worth $36,000. Finally, FSA Wealth Management LLC grew its holdings in shares of Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after buying an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on AMGN shares. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Morgan Stanley dropped their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price target on shares of Amgen in a report on Thursday, September 26th. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and increased their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $333.50.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $0.94 during trading on Friday, hitting $319.22. 1,826,772 shares of the stock were exchanged, compared to its average volume of 2,418,089. The company has a market capitalization of $171.53 billion, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 2.84 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The company’s fifty day simple moving average is $324.47 and its 200-day simple moving average is $315.19. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 181.58%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the business earned $4.96 EPS. The firm’s revenue was up 23.2% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.48 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.